IL6 and diffuse large B-cell lymphoma: The same study shows that loss of CD37 in neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlates with activation of the IL-6 signaling pathway and with worse progression-free and overall survival.